{
    "clinical_study": {
        "@rank": "125965", 
        "acronym": "IEM", 
        "arm_group": [
            {
                "arm_group_label": "PF-05089771 1600 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo comparator: matching placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single oral dose of placebo for PF-05089771 1600 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of single doses of\n      PF-05089771 against placebo in treatment of pain in patients with primary, inherited\n      erythromelalgia."
        }, 
        "brief_title": "Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Inherited Erythromelalgia", 
        "condition_browse": {
            "mesh_term": "Erythromelalgia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and or female subjects between the ages of 18-78 years\n\n          -  Subject has clinical signs of IEM\n\n          -  Minimum BMI 17.5kg/m2 and total body weight >50kg\n\n        Exclusion Criteria:\n\n          -  Other severe pain conditions, e.g. rheumatologic, that may impair subject's\n             self-assessment of pain due to IEM.\n\n          -  Evidence of clinically significant hypertension, clinically significant\n             hematological, dermatological, renal, endocrine (except diabetes mellitus),\n             pulmonary, gastrointestinal, cardiovascular, hepatic, neurological (other than IEM),\n             or allergic disease (including drug allergies but excluding untreated asymptomatic\n             seasonal allergies).\n\n          -  Subjects with severe obesity."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "78 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01769274", 
            "org_study_id": "B3291006"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-05089771 1600 mg", 
                "description": "A single oral dose of PF-05089771 1600 mg  solution to be administered on Day 1 of each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of PF-05089771 will be adminstered.", 
                "intervention_name": "PF-05089771", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo comparator: matching placebo", 
                "description": "Placebo for PF-05089771 1600 mg solution administered in each treatment session. There are 2 treatment sessions, therefore 2 single oral  doses of placebo  will be administered.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "July 30, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3291006&StudyName=%20Evaluation%20Of%20The%20Efficacy%20And%20Safety%20Of%20Single%20Doses%20Of%20PF-05089771%20In%20Patients%20With%20Primary%20%28Inherited%29%20Erythromelalgia"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double Blind Third Party Open Placebo-Controlled Exploratory Study To Evaluate The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Average pain score postdose based on  Pain Intensity Numerical Rating Scale (PI-NRS) scores", 
            "safety_issue": "No", 
            "time_frame": "0-4 hr postdose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01769274"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum pain score  postdose based on Pain Intensity Numerical Rating Scale scores.", 
                "safety_issue": "No", 
                "time_frame": "0-4 hr postdose"
            }, 
            {
                "measure": "Duration of time above  Pain Intensity Numerical Rating Scale score of 5.", 
                "safety_issue": "No", 
                "time_frame": "0-4hr postdose"
            }, 
            {
                "measure": "Average pain score post  Evoked Pain (EP) timepoint 2 based on  Pain Intensity Numerical Rating Scale scores.", 
                "safety_issue": "No", 
                "time_frame": "4-8 hr postdose"
            }, 
            {
                "measure": "Maximum pain score post  Evoked Pain timepoint 2 based on maximum Pain Intensity Numerical Rating Scale scores.", 
                "safety_issue": "No", 
                "time_frame": "4-8h hr postdose"
            }, 
            {
                "measure": "Duration of time above  Pain Intensity Numerical Rating Scale score of 5 in the period post Evoked Pain timepoint 2", 
                "safety_issue": "No", 
                "time_frame": "4-8 hr postdose"
            }, 
            {
                "measure": "Average pain score post Evoked Pain timepoint 3 based on Pain Intensity Numerical Rating scale scores", 
                "safety_issue": "No", 
                "time_frame": "8-10 hr postdose"
            }, 
            {
                "measure": "Maximum pain score post Evoked Pain timepoint 3 based on maximum  Pain Intensity Numerical Rating Scale scores", 
                "safety_issue": "No", 
                "time_frame": "8-10 hr postdose"
            }, 
            {
                "measure": "Duration of time above  Pain Intensity Numerical Rating Scale score  of 5 post  Evoked Pain timepoint 3", 
                "safety_issue": "No", 
                "time_frame": "8-10 hr postdose"
            }, 
            {
                "measure": "Average  pain score post  Evoked Pain timepoint 4  based on  Pain Intensity Numerical Rating scale scores", 
                "safety_issue": "No", 
                "time_frame": "24-28 hr postdose"
            }, 
            {
                "measure": "Maximum pain score post Evoked Pain timepoint 4 based on maximum  Pain Intensity Numerical Rating Scale  scores", 
                "safety_issue": "No", 
                "time_frame": "24-28 hr postdose"
            }, 
            {
                "measure": "Duration of time above  Pain Intensity Numerical Rating Scale score of 5 post Evoked Pain timepoint 4", 
                "safety_issue": "No", 
                "time_frame": "24-28 hr postdose"
            }, 
            {
                "measure": "Patient's global satisfaction with study medication based on categorical rating scale", 
                "safety_issue": "No", 
                "time_frame": "4 hr postdose"
            }, 
            {
                "measure": "Time to first rescue therapy or medication post dose", 
                "safety_issue": "No", 
                "time_frame": "0-28 hr postdose"
            }, 
            {
                "measure": "Plasma concentrations of  PF-05089771,  maximum observed concentration (Cmax), time to maximum concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 predose, then 0.5hr, 2hr, 4hr, 6hr and 24hr postdose"
            }, 
            {
                "measure": "Type, incidence and severity of Laboratory test result abnormalities as a measure of safety and toleration", 
                "safety_issue": "No", 
                "time_frame": "Day 0, Day 2; 24 hr postdose"
            }, 
            {
                "measure": "Type, incidence and severity of Adverse Events in study subjects", 
                "safety_issue": "No", 
                "time_frame": "up to 28 days post last dose"
            }, 
            {
                "measure": "Blood pressure changes of clinical significance, as a measure of safety and toleration", 
                "safety_issue": "No", 
                "time_frame": "Day -2, Day -1, Predose and 6hr post dose"
            }, 
            {
                "measure": "Electrocardiogram changes of clinical significance, as a measure of safety and toleration", 
                "safety_issue": "No", 
                "time_frame": "Day -2, predose, 6 hr 24 hr post dose"
            }, 
            {
                "measure": "Pulse rate changes of clinical significance, as a measure of safety and toleration", 
                "safety_issue": "No", 
                "time_frame": "Day -2, Day -1, Predose and 6hr post dose"
            }, 
            {
                "measure": "Reason for first rescue therapy or medication postdose", 
                "safety_issue": "No", 
                "time_frame": "0-28 hr postdose"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}